Objective: To review clinical data on idarucizumab for the reversal of dabigatran-associated anticoagulation. Data Sources: Articles for this review were identified via PubMed using the MeSH term dabigatran combined with the keyword idarucizumab. Additional online searches via PubMed and Google Scholar were conducted for both prescribing and cost information. Study Selection and Data Extraction: English-language clinical trials published between 1946 and May 2016 were included for review. Bibliographies of selected articles were also manually reviewed for relevant publications that focused on reversal strategies for dabigatran-associated anticoagulation. Data Synthesis: The safety and tolerability of idarucizumab has been evaluated in 3 phase I clinical trials. The use of idarucizumab for reversing dabigatran-associated anticoagulation is also being evaluated in the phase III RE-VERSE AD study. Interim results of the RE-VERSE AD study have been published. Conclusions: Idarucizumab rapidly neutralizes the anticoagulant effect of dabigatran in healthy volunteers, in patients with life-threatening bleeding, and in patients requiring urgent surgery that cannot be delayed. These observations are largely based on laboratory assessments rather than clinical outcomes. Idarucizumab is well tolerated, and it does not appear to induce procoagulant or immunogenic adverse effects.
RuffCTGiuglianoRPBraunwaldE. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962.
3.
HulleTVDKooimanJExterPLDDekkersOMKlokFAHuismanMV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12:320-328.
4.
MillerCSGrandiSMShimonyAFilionKBEisenbergMJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.
5.
HernandezIBaikSHPiñeraAZhangY. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18.
6.
MajeedAHwangH-GConnollySJ. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325-2332.
7.
SouthworthMRReichmanMEUngerEF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272-1274.
8.
EikelboomJWWallentinLConnollySJ. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation. 2011;123:2363-2372.
9.
BrunettiLBandaliF. Dabigatran: is there a role for coagulation assays in guiding therapy?Ann Pharmacother. 2013;47:828-840.
10.
AlikhanRRaymentRKeelingD. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J. 2013;31:163-168.
SchieleFRynJVCanadaK. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554-3562.
13.
GlundSMoschettiVNorrisS. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943-951.
14.
GlundSStangierJSchmohlM. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680-690.
15.
GlundSStangierJSchmohlM. Idarucizumab, a specific antidote for dabigatran: immediate, complete, and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Abstract presented at: 56th American Society of Hematology Annual Meeting and Exhibition; December 8, 2014; San Francisco, CA.
16.
PollackCVReillyPAEikelboomJ. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511-520.
17.
GanetskyMBabuKMSalhanickSDBrownRSBoyerEW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7:281-287.
18.
Garnock-JonesKP. Dabigatran etexilate. Am J Cardiovasc Drugs. 2011;11:57-72.
PollackCVReillyPEikelboomJ. Idarucizumab for reversal of the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. J Am Coll Cardiol. 2016;67:664.
23.
WinklerAMTormeyCA. Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients. Am J Clin Pathol. 2013;140:610-622.
24.
GrottkeOAisenbergJBernsteinR. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. Crit Care. 2016;20:115.
25.
RynJVSchurerJKink-EibandMClemensA. Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology. 2014;120:1429-1440.
26.
HonickelMTreutlerSRynJTillmannSRossaintRGrottkeO. Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab. Thromb Haemost. 2015;113:728-740.
27.
AwadNIBrunettiLJuurlinkDN. Enhanced elimination of dabigatran through extracorporeal methods. J Med Toxicol. 2014;11:85-95.
28.
KumarRSmithREHenryBL. A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage: a single-center university hospital experience. J Intensive Care Med. 2014;30:462-472.
29.
KhadzhynovDWagnerFFormellaS. Effective elimination of dabigatran by haemodialysis. Thromb Haemost. 2013;109:596-605.
30.
SinghTMawTTHenryBL. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol. 2013;8:1533-1539.
31.
FronteraJALewinJJIIIRabinsteinAA. Guideline for reversal of antithrombotics in intracranial hemorrhage. Neurocrit Care. 2015;24:6-46.
32.
ZhouWSchwartingSIllanesS. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-3599.
33.
LambourneMDEltringham-SmithLJGataianceSArnoldDMCrowtherMASheffieldWP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost. 2012;10:1830-1840.
34.
van RynJSeigerPKink-EibandMGansserDClemensA. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract no 1065]. Abstract presented at: 51st ASH Annual Meeting and Exposition; December 5, 2009; New Orleans, LA. http://ash.confex.com/ash/2009/webprogram/Paper21383.html. Accessed June 29, 2016.
35.
JacqueminMToelenJSchoetersJ. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders. J Thromb Haemost. 2015;13:2087-2092.
